查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
体外诊断检测流程概况：第七版（2025-2030）
市场调查报告书
商品编码
1844742

体外诊断检测流程概况：第七版（2025-2030）

IVD Test Procedure Volumes, 7th Edition (2025-2030)
出版日期: | 出版商: Kalorama Information | 英文 275 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

受次世代定序 (NGS)、微流控和精准医疗等领域强劲技术进步的推动，全球体外诊断 (IVD) 市场将在 2025 年继续扩张，并将诊断转变为更个人化、以患者为中心的领域。 "体外诊断检测流程概览：第七版（2025-2030）" 对全球检测趋势进行了全面、数据驱动的分析，是对 Kalorama Information 旗舰出版物 "体外诊断 (IVD) 检测市场：第十八版（2025-2030）" 的重要补充。

量化全球检测格局

本报告深入分析了体外诊断 (IVD) 在主要检测类别中的应用，包括分子诊断、临床化学、免疫分析、血液学、凝血、微生物学、血库和组织学/细胞学。报告还量化了主要全球市场的检测数量、平均单次检测成本和区域差异。报告预测了到 2030 年的发展趋势，并深入分析了影响全球诊断市场的检测利用趋势、成本趋势以及不断变化的区域检测模式。

技术进步重塑诊断

随着 IVD 产业摆脱疫情驱动的需求，包括自我检测、居家诊断和即时检测 (POC) 解决方案在内的新模式正在加速普及，并重塑医疗保健服务模式。

同时，分子诊断和癌症诊断的成长印证了该领域对早期检测和透过液体活检及基因组检测进行非侵入性监测的关注。这些进展与全球精准医疗的发展趋势相符，但也带来了与成本、监管和公平取得相关的新挑战。

应对经济和监管压力

本报告将这些市场推动因素置于快速变化的监管和经济环境中进行分析。面对欧盟体外诊断医疗器材法规 (IVDR) 和不断变化的美国食品药物管理局 (FDA) 框架下日益严格的审查，製造商必须应对复杂的审批流程，同时还要应对影响报销和应用的支付方压力。技术进步、可负担性和可扩展性之间的平衡将决定体外诊断 (IVD) 发展的下一阶段。

研究方法与策略价值

本研究方法是 Kalorama 独有的，能够提供准确、透明且可操作的体外诊断药物生产和销售估算。这使高阶主管、策略家和投资者能够对标绩效、识别成长机会，并使产品组合与新兴诊断趋势保持一致。

体外诊断决策者必备的资源

对于希望了解体外诊断 (IVD) 市场发展方向以及未来五年 IVD 需求将如何推动创新、投资和市场准入的公司而言， "体外诊断检测程序量，第 7 版 (2025-2030)" 是策略决策的必备资源。

目录

第一章：摘要整理

  • 体外诊断检测量估算与预测
  • 范围与研究方法

第二章：引言

  • 范围
  • 概述
  • 产业趋势
  • 人口趋势
    • 全球人口与老化
    • 劳动力减少
  • 慢性病增加
  • 个人化医疗
  • 严重疾病威胁
    • 蜱传疾病 (TBD)
    • 寨卡病毒
    • 恰加斯病
    • 登革热
    • 伊波拉病毒
    • 基孔肯雅病毒
    • 中东呼吸道症候群冠状病毒 (MERS-CoV)
    • 马堡病毒
    • 猴痘
  • 新兴国家与市场

第三章 体外诊断 (IVD) 检测领域

  • 体外诊断 (IVD) 检测趋势
  • 区隔市场成长预测
    • 即时侦测 (POC)侦测
    • 临床化学
    • 免疫分析
    • 质谱分析（免疫学）
    • 分子检测
    • 血液学
    • 凝血
    • 传统微生物学
    • 血型鑑定
    • 组织学/细胞学
  • 区隔产品销售

第四章 全球体外诊断市场

  • 概述
  • 北美
    • 美国
    • 加拿大
  • 墨西哥和南美洲
    • 巴西
    • 墨西哥
    • 其他国家和地区
    • 阿根廷
    • 智利
    • 哥伦比亚
    • 秘鲁
    • 委内瑞拉
    • 其他国家和地区地区
  • 西欧
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他国家和地区
    • 奥地利
    • 比利时
    • 丹麦
    • 芬兰
    • 希腊
    • 爱尔兰
    • 挪威
    • 荷兰
    • 葡萄牙
    • 瑞典
    • 瑞士
    • 其他国家和地区
  • 东欧
    • 俄罗斯
    • 东欧其他国家
    • 捷克
    • 匈牙利
    • 波兰
    • 罗马尼亚
    • 乌克兰
    • 其他国家
  • 亚洲太平洋
    • 中国
    • 日本
    • 其他国家和地区
    • 澳大利亚
    • 香港
    • 印度
    • 印尼
    • 马来西亚
    • 巴基斯坦
    • 菲律宾
    • 新加坡
    • 韩国
    • 台湾
    • 泰国
    • 越南
    • 纽西兰
    • 其他国家和地区
  • 中东
    • 土耳其
    • 其他中东国家
    • 伊朗
    • 伊拉克
    • 以色列
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 其他国家
  • 非洲
    • 奈及利亚
    • 南非
    • 其他国家区域

第五章 即时检验 (POC) 流程

  • 范围
  • 引言
    • 即时检定 (POC) 概述
  • 全球 POC 侦测量（依检测类型划分）
  • POC 自测
  • POC 自测产品销售
  • 价格趋势
  • POC 专业侦测
  • POC 体外诊断 (IVD) 产品销售
  • 价格趋势

第六章：临床化学检测流程

  • 范围
  • 引言
  • 检测类型
  • 普通化学
  • 酶
  • 葡萄糖
  • 脂质
  • 蛋白质
  • 其他化合物
  • 血气和电解质
  • 尿液检测
  • 全球临床化学产品销售
  • 价格趋势

    第七章 免疫测定

    • 范围
    • 引言
    • 标记技术
      • 酵素免疫测定
      • 化学发光磁珠免疫测定 (CMIA)
      • 萤光偏光免疫测定 (FPIA)
      • 放射免疫测定法 (RIA)
    • 检测技术与产品销售
      • 心臟标记
      • 肿瘤标记
      • 自体免疫疾病
      • 过敏症状
      • 甲状腺疾病
      • 蛋白质
      • 阿兹海默症疾病
      • 贫血
      • 不孕症检测
      • 治疗药物监测
      • 维生素D
      • 糖尿病/糖化血红素
      • 滥用药物
      • 传染病
    • 设备
    • 价格趋势

    第八章 分子侦测程序

    • 引言
    • 检测类型
      • 检测技术
      • 传染病
      • 血液检测
      • 癌症
      • 移植配对
      • 血栓形成相关单核苷酸多态性（SNP）
      • 遗传性疾病
      • 其他分子检测
      • 产前检测
    • 分子体外诊断（IVD）产品全球销售额
    • 价格趋势

    第九章：实验室血液学检测程序

    • 范围
    • 引言
    • 检测类型
    • 血液学产品的全球销售额
    • 价格趋势

    第十章：凝血检测程序

    • 引言
    • 检测类型
    • 凝血产品的全球销售额
    • 价格趋势

    第十一章：微生物学检测技术

    • 范围
    • 引言
    • 检测类型
      • 自动化鑑定/药敏试验试剂盒及试剂
      • 手动试剂盒及试剂
      • 血液培养
      • 显色培养基
      • 快速微生物学检测检测
      • 质谱分析
    • 传统体外诊断微生物产品的全球销售额
      • 鑑定/药敏试验试剂盒及试剂
      • 血液培养
      • 显色培养基
      • 快速微生物检测
      • 质谱分析
    • 价格趋势

    第十二章：血型鑑定技术

    • 引言
    • 检测类型
    • 血型鑑定产品销售
    • 价格趋势

    第十三章：组织学/细胞学检测程序

    • 范围
    • 引言
    • 检测类型
      • 免疫组织化学检测
      • 原位杂交检测项目
      • 巴氏抹片检查
      • 传统非巴氏染色
      • 循环肿瘤细胞
      • 流式细胞仪
    • 组织学/细胞学体外诊断产品销售
    • 价格趋势

    第十四章：公司简介

    • 引言
    • ABBOTT DIAGNOSTICS
    • AGILENT TECHNOLOGIES
    • BECTON, DICKINSON AND COMPANY (BD)
    • BIOMERIEUX INC.
    • BIO-RAD LABORATORIES, INC.
    • DANAHER CORPORATION
    • DEXCOM
    • DIASORIN
    • EXACT SCIENCES
    • HOLOGIC, INC.
    • ILLUMINA
    • NATERA
    • QUIDELORTHO CORPORATION
    • REVVITY
    • ROCHE DIAGNOSTICS
    • SIEMENS HEALTHINEERS (SIEMENS)
    • SYSMEX CORPORATION
    • THERMO FISHER SCIENTIFIC INC.
    • WERFEN
    • 简介目录
    Product Code: 25-025KA

    The global in vitro diagnostics (IVD) market continues to expand in 2025, driven by powerful innovations in next-generation sequencing (NGS), microfluidics, and precision medicine that are transforming diagnostics into a more personalized, patient-centric field. "IVD Test Procedure Volumes, 7th Edition (2025-2030)" provides a comprehensive, data-driven analysis of global test volume trends, serving as a critical companion to Kalorama Information's flagship publication, "The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 18th Edition (2025-2030)".

    Quantifying the Global Testing Landscape

    This report delivers an in-depth examination of IVD procedures across major testing categories-including molecular diagnostics, clinical chemistry, immunoassays, hematology, coagulation, microbiology, blood banking, and histology/cytology. It quantifies the number of tests performed, the average cost per procedure, and regional variations across key markets worldwide. With forecasts extending through 2030, the study offers essential insight into test utilization trends, cost dynamics, and evolving regional testing patterns that are shaping the global diagnostics landscape.

    Technological Advancements Reshaping Diagnostics

    As the IVD industry evolves beyond pandemic-driven demand, new paradigms in self-testing, home-based diagnostics, and point-of-care (POC) solutions are accelerating accessibility and reshaping healthcare delivery. Meanwhile, growth in molecular and cancer diagnostics underscores the sector's pivot toward early detection and non-invasive monitoring through liquid biopsy and genomic testing. These advancements align with the global push toward precision medicine-but also introduce new challenges related to cost, regulation, and equitable access.

    Navigating Economic and Regulatory Pressures

    This report contextualizes these market drivers within a rapidly changing regulatory and economic environment. With rising scrutiny under the EU's IVDR and FDA's evolving frameworks, manufacturers must navigate complex approval pathways while addressing payer pressures that impact reimbursement and adoption. The balance between technological advancement, affordability, and scalability will define the next stage of IVD growth.

    Methodology and Strategic Value

    Drawing on Kalorama's proprietary methodologies, this study presents accurate, transparent, and actionable estimates of IVD procedure volumes and revenues-empowering executives, strategists, and investors to benchmark performance, identify growth opportunities, and align product portfolios with emerging diagnostic trends.

    An Essential Resource for IVD Decision-Makers

    For organizations seeking to understand where the IVD market is headed-and how procedural demand will drive innovation, investment, and access over the next five years-"IVD Test Procedure Volumes, 7th Edition (2025-2030)" is an indispensable resource for strategic decision-making.

    TABLE OF CONTENTS

    CHAPTER ONE: EXECUTIVE SUMMARY

    • IVD PROCEDURE VOLUME ESTIMATE AND FORECAST
      • Figure 1-1: Global IVD Procedure Volumes, 2025 and 2030 (in millions # volume)
    • SCOPE & METHODOLOGY

    CHAPTER TWO: INTRODUCTION

    • SCOPE
    • OVERVIEW
    • INDUSTRY TRENDS
      • Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2025-2030 (in millions # volume; $ million)
    • DEMOGRAPHIC TRENDS
      • Global Population and Aging
        • Figure 2-1: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
        • Figure 2-2: Global Population Distribution, 2022
        • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 [Australia, Brazil, Canada, China, China (Hong Kong SAR), France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, Singapore, South Africa, Spain, Turkey, United Kingdom, United States, World]
      • Workforce Reduction
        • Table 2-3: WHO Model List of Essential In Vitro Diagnostics (EDL)
    • INCREASE IN CHRONIC DISEASES
      • Figure 2-3: Leading Causes of Death Globally, 2021* (number of deaths in millions)
    • PERSONALIZED MEDICINE
    • HIGH-CONSEQUENCE DISEASE THREATS
      • Table 2-4: Selected Companies Marketing Products Addressing High-Consequence Infectious Disease Threats
      • Tickborne Diseases (TBDs)
      • Zika
      • Chagas
      • IVD Vendors Active in Chagas Diagnostics
      • Dengue
      • Ebola
      • Chikungunya
      • Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
      • Marburg
      • Monkeypox
    • EMERGING AND EMERGED MARKETS
      • Table 2-5: Developed/Developing Economies, UN Classification*, 2025
      • Figure 2-4: Developed vs. Developing IVD Market Shares, 2025 and Projected 2030 (%)
      • Where Are the Best Markets?
        • Table 2-6: Countries To Watch for IVD Opportunities, by Total Population and Percent Urban, 2025 [Australia, Brazil, China, France, Germany, Hungary, India, Mexico, Netherlands, Peru, Poland, Romania, Saudi Arabia, South Africa, South Korea, Sweden, Switzerland, Turkey, United Kingdom, United States]
      • Economic Growth and the Expanding Middle Class

    CHAPTER THREE: IVD TESTING SEGMENTS

    • IVD TESTING TRENDS
      • Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
    • SEGMENT GROWTH PROJECTIONS
      • Point-of-Care (POC) Testing
      • Clinical Chemistry
      • Immunoassays
      • Mass Spectrometry (Immuno)
      • Molecular Assays
      • Hematology
      • Coagulation
      • Conventional Microbiology
      • Blood Grouping/Typing
      • Histology/Cytology
    • SEGMENT PRODUCT SALES
      • Table 3-5: IVD Product Sales including Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-6: IVD Product Sales including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-7: IVD Product Sales excluding Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-8: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]

    CHAPTER FOUR: GLOBAL IVD MARKETS

    • GENERAL
      • Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2025-2030 (millions) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
      • Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2025-2030 (%) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
    • NORTH AMERICA
      • United States
      • Canada
    • MEXICO, CENTRAL, & SOUTH AMERICA
      • Brazil
      • Mexico
      • Other Central & South America
      • Argentina
      • Chile
      • Colombia
      • Peru
      • Venezuela
      • All Other Countries & Territories
    • WESTERN EUROPE
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
      • Other Western Europe
      • Austria
      • Belgium
      • Denmark
      • Finland
      • Greece
      • Ireland
      • Norway
      • Netherlands
      • Portugal
      • Sweden
      • Switzerland
      • All Other Countries & Territories
    • EASTERN EUROPE
      • Russia
      • Other Eastern Europe
      • Czech Republic
      • Hungary
      • Poland
      • Romania
      • Ukraine
      • All Other Countries
    • ASIA/PACIFIC
      • China
      • Japan
      • Other Asian Countries and Territories
      • Australia
      • Hong Kong
      • India
      • Indonesia
      • Malaysia
      • Pakistan
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
      • New Zealand
      • All Other Countries & Territories
    • MIDDLE EAST
      • Turkey
      • Other Middle East
      • Iran
      • Iraq
      • Israel
      • Saudi Arabia
      • United Arab Emirates
      • All Other Countries
    • AFRICA
      • Nigeria
      • South Africa
      • All Other Countries & Territories

    CHAPTER FIVE: POINT-OF-CARE (POC) PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Point-of-Care (POC) Testing Overview
    • GLOBAL POC PROCEDURE VOLUME BY TEST TYPE
      • Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2025-2030
      • Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2025-20230
      • Figure 5-1: Regional POC Procedure Volumes including blood glucose tests, 2025 [Europe, Japan, United States, Rest of World]
    • POC SELF TESTS
      • Table 5-3: POC Self-Test Procedural Volume, by Type, 2025-2030 (millions) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
      • Traditional Blood Glucose Monitoring Activities
      • Continuous Blood Glucose Monitoring
      • Pregnancy and Fertility Testing
      • Coagulation Testing
      • Fecal Occult Blood Testing
      • Drugs of Abuse Testing
      • H. pylori Testing
      • HIV Testing
      • Infectious Disease
      • Cholesterol Testing
      • POC Urinalysis Testing
      • Other POC Self-Testing
    • POC SELF-TESTING PRODUCT SALES
      • Table 5-4: POC Self-Test Product Sales, by Type, 2025-2030 ($ million) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
    • PRICING TRENDS
      • Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2025-2030 [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
    • POC PROFESSIONAL TESTING
      • Table 5-6: POC Professional Procedural Volume, by Type, 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
      • POC Professional Blood Glucose Testing Procedures
      • POC Professional Critical Care Testing
      • POC Fertility Testing
      • POC Professional Infectious Disease Testing
      • POC Professional Cardiac Marker Testing
      • POC Professional Cholesterol/Lipid Testing
      • POC Professional Coagulation Testing
      • POC Professional HbA1C Testing
      • POC Professional Hematology Testing
      • POC Professional Fecal Occult Blood Screening
      • POC Professional Drugs of Abuse Testing
      • POC Professional Urinalysis Testing
      • Other POC Professional Testing
    • POC IVD PRODUCT SALES
      • Table 5-7: POC Professional IVD Product Sales, by Type, 2025-2030 ($ million) [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
    • PRICING TRENDS
      • Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]

    CHAPTER SIX: CLINICAL CHEMISTRY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]
      • Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
    • TYPES OF TESTS
      • General Chemistry
      • Enzymes
      • Glucose
      • Lipids
      • Proteins
      • Other Compounds
      • Blood Gases & Electrolytes
      • Urinalysis
    • GLOBAL SALES OF CLINICAL CHEMISTRY PRODUCTS
      • Table 6-2: Clinical Chemistry Product Sales, by Type, 2025-2030 ($ million) [Blood Gas Analysis, General Chemistry, Urinalysis]
    • PRICING TRENDS
      • Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]

    CHAPTER SEVEN: IMMUNOASSAY PROCEDURES

    • SCOPE
    • INTRODUCTION
    • LABELING TECHNIQUES
      • Enzyme Immunoassays
      • Chemiluminescent Magnetic Immunoassays (CMIAs)
      • Fluorescence Polarization Immunoassays (FPIAs)
      • Radioimmunoassays (RIAs)
        • Table 7-1: Immunoassay Procedural Volume, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
        • Figure 7-1: Regional Immunoassay Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TESTING PROCEDURES & PRODUCT SALES
      • Table 7-2: Immunoassay Product Sales, by Type, 2025-2030 ($ million) [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
      • Cardiac Markers
      • Tumor Markers
      • Autoimmune Conditions
      • Allergy Conditions
      • Thyroid Conditions
      • Proteins
      • Alzheimer's Disease
      • Anemia
      • Fertility Testing
      • Therapeutic Drug Monitoring
      • Vitamin D
      • Diabetes/HbA1c
      • Drugs of Abuse
      • Infectious Diseases
        • Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2025-2030 [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
        • Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
    • INSTRUMENTS
    • PRICING TRENDS
      • Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]

    CHAPTER EIGHT: MOLECULAR TESTING PROCEDURES

    • INTRODUCTION
      • Table 8-1: Molecular Assay Procedural Volume, by Type, 2025-2030 (millions) [Molecular - Other, Molecular Assays - Oncology, Molecular Blood Bank, Molecular Histology - Non Cancer, Molecular Histology - Cancer, Molecular HPV, Molecular Infectious Disease, Molecular Inherited Diseases, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]
      • Figure 8-1: Regional Molecular Assay Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
    • TYPES OF TESTS
      • Testing Technologies
      • Infectious Diseases
        • Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2025-2030 [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
      • Blood Screening
      • Cancer
      • Transplant Matching
      • Thrombophilia SNPs
      • Inherited Diseases
      • Other Molecular Tests
      • Prenatal
    • GLOBAL SALES OF MOLECULAR IVD PRODUCTS
      • Table 8-3: Molecular Assay Product Sales, by Type, 2025-2030 ($ million) [Genetic Testing/Inherited Disease, Molecular Assays - Oncology, Molecular Blood bank, Molecular Histology - Cancer, Molecular Histology - Non Cancer, Molecular HPV, Molecular Infectious disease, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Other Molecular, Prenatal]
      • Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
    • PRICING TRENDS
      • Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2025-2030 [Molecular Assays - Oncology, Molecular Blood bank, Molecular Histology - cancer, Molecular Histology - non cancer, Molecular HPV, Molecular Infectious disease, Molecular Inherited Diseases, Molecular Other, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Prenatal]

    CHAPTER NINE: LABORATORY-BASED HEMATOLOGY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]
      • Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
    • TYPES OF TESTS
    • GLOBAL SALES OF HEMATOLOGY PRODUCTS
      • Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2025-2030 ($ million) [Complete Blood Count, Other Hematology Tests]
    • PRICING TRENDS
      • Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]

    CHAPTER TEN: COAGULATION TESTING PROCEDURES

    • INTRODUCTION
      • Table 10-1: Coagulation Procedural Volume, 2025-2030 [D-dimer, PT/INR]
      • Figure 10-1: US/ROW Coagulation Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TYPES OF TESTS
    • GLOBAL SALES OF COAGULATION PRODUCTS
      • Table 10-2: Coagulation Product Sales, 2025-2030 ($ million) (D-dimer, PT/INR)
    • PRICING TRENDS
      • Table 10-3: Coagulation $ Products per Procedure, 2025-2030 [D-dimer, PT/INR]

    CHAPTER ELEVEN: MICROBIOLOGY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
    • TYPES OF TESTS
      • ID/AST Automated Panels & Reagents
      • Manual Panels & Reagents
      • Blood Culture
      • Chromogenic Media
      • Rapid Microbiological Tests
      • Mass Spectrometry
    • GLOBAL SALES OF CONVENTIONAL IVD MICROBIOLOGY PRODUCTS
      • ID/AST Panels & Reagents
      • Blood Culture
      • Chromogenic Media
      • Rapid Microbiological Tests
      • Mass Spectrometry
        • Table 11-2: Conventional Microbiology Product Sales, by Type, 2025-2030 ($ million) [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
    • PRICING TRENDS
      • Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]

    CHAPTER TWELVE: BLOOD GROUPING/TYPING PROCEDURES

    • INTRODUCTION
      • Table 12-1: Blood Grouping/Typing Procedure Volumes, 2025-2030
      • Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TYPES OF TESTS
    • BLOOD GROUPING/TYPING PRODUCT SALES
      • Table 12-2: Blood Grouping/Typing Product Sales, 2025-2030 ($ million)
    • PRICING TRENDS
      • Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2025-2030

    CHAPTER THIRTEEN: HISTOLOGY/CYTOLOGY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 13-1: Histology/Cytology Procedural Volume, by Type, 2025-2030 [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
      • Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TYPES OF TESTS
      • Immunohistochemistry Tests
      • In Situ Hybridization Tests
      • Pap Tests
      • Traditional Non-Pap Stains
      • Circulating Tumor Cells
      • Flow Cytometry
    • HISTOLOGY/CYTOLOGY IVD PRODUCT SALES
      • Table 13-2: Histology/Cytology Product Sales, by Type, 2025-2030 ($ million) [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
    • PRICING TRENDS
      • Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2025-2030

    CHAPTER FOURTEEN: COMPANY PROFILES

    • INTRODUCTION
      • Table 14-1: Revenues of Selected Top 20 IVD Companies, 2024 and estimated 2025 ($ million) [Abbott Diagnostics, Agilent, Becton Dickinson, bioMerieux, Bio-Rad Laboratories, Bruker - CALID, Danaher, Dexcom, Diasorin, Exact Sciences, Hologic, Illumina, Natera, QuidelOrtho, Revvity, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen]
    • ABBOTT DIAGNOSTICS
      • Recent Revenue History
        • Table 14-2: Abbott Diagnostic Revenues, 2022-2024 ($ million)
        • Table 14-3: Abbott Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
    • AGILENT TECHNOLOGIES
      • Recent Revenue History
        • Table 14-4: Agilent Revenues, 2022-2024 (million $)
    • BECTON, DICKINSON AND COMPANY (BD)
      • Recent Revenue History
        • Table 14-5: BD Diagnostic Revenues, 2022-2024 (million $) FYE Sept 30
    • BIOMERIEUX INC.
      • Recent Revenue History
        • Table 14-6: bioMerieux IVD Revenues, 2022-2024 (Euro million)
    • BIO-RAD LABORATORIES, INC.
      • Recent Revenue History
        • Table 14-7: Bio-Rad Diagnostics Revenues, 2022-2024 ($ million)
    • DANAHER CORPORATION
      • Recent Revenue History
        • Table 14-8: Danaher Global IVD Diagnostic Sales, 2022-2024 ($ million)
    • DEXCOM
      • Recent Revenue History
        • Table 14-9: Dexcom IVD Diagnostic Sales, 2022-2024 ($ million)
    • DIASORIN
      • Recent Revenue History
        • Table 14-10: Diasorin Revenues, 2022-2024 (million Euro )
    • EXACT SCIENCES
      • Recent Revenue History
        • Table 14-11: Exact Sciences Revenues, 2022-2024 ($ million)
    • HOLOGIC, INC.
      • Recent Revenue History
        • Table 14-12: Hologic Revenues, 2022-2024 ($ million)
    • ILLUMINA
      • Recent Revenue History
        • Table 14-13: Illumina Diagnostics Revenues, 2022-2024 ($ million)
      • Recent Revenue History
        • Table 14-14: Mindray Revenue History, 2022-2024 (billion CNY)
    • NATERA
      • Recent Revenue History
        • Table 14-15: Natera Revenue History, 2022-2024 ($ million)
    • QUIDELORTHO CORPORATION
      • Recent Revenue History
        • Table 14-16: QuidelOrtho Revenue History, 2022-2024 ($ million)
        • Table 14-17: QuidelOrtho Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
    • REVVITY
      • Table 14-18: Revvity Revenue History, 2022-2024 ($ million, estimated)
    • ROCHE DIAGNOSTICS
      • Recent Revenue History
        • Table 14-19: Roche Diagnostics IVD Revenues, 2022-2024 (CHF million)
        • Table 14-20: Roche Diagnostic Revenues, by Segment, 2023-2024 (CHF million)
    • SIEMENS HEALTHINEERS (SIEMENS)
      • Recent Revenue History
        • Table 14-21: Siemens Healthineers IVD Revenues, 2022-2024 (Euro million)
    • SYSMEX CORPORATION
      • Recent Revenue History
        • Table 14-22: Sysmex IVD Revenues, 2022-2024 (FY March 31) (billions of yen)
        • Table 14-23: Sysmex Diagnostic Revenues, by Segment, 2022-2024 (billions of yen)
    • THERMO FISHER SCIENTIFIC INC.
      • Recent Revenue History
        • Table 14-24: Thermo Fischer IVD Revenues, 2022-2024 ($ million)
    • WERFEN
      • Recent Revenue History
        • Table 14-25: Werfen IVD Revenues, 2022-2024 (Euro billion)